McKesson raises 2026 EPS guidance to $38.35–$38.85 while advancing oncology and specialty platforms

Q2 2026 Management View Brian Tyler, CEO, reported "strong second quarter results, which reflect sustained momentum in our ...

Alto Ingredients outlines $18M Section 45Z tax credits opportunity while advancing CO2 and export strategies

Q3 2025 Management View CEO Bryon McGregor reported, “Strong market conditions combined with the benefits realized from our ...